CANCEROUS IMMUNOGLOBULINS AND CA215: IMPLICATIONS IN CANCER IMMUNOLOGY

Gregory Lee

UBC Center for Reproductive Health, Faculty of Medicine, The University of British Columbia, Vancouver, BC, V6H 3N1, Canada

Received 2012-07-28, Revised 2012-09-15; Accepted 2012-09-08

ABSTRACT

Immunoglobulins are typically expressed by B cells in our normal immune system. However, certain normal human tissues, such as hyperplastic epithelial cells, cells of the immunologically privileged sites and the majority of cancer cells, have also been found to be sites of immunoglobulin production. Current research is lacking in regards to the differential immunoglobulin expression, the underlying mechanisms of action and the biological implications of these cancerous immunoglobulins in cancer immunology. This article reviews the etiology of atypical immunoglobulin expression in normal non-B cells and cancer cells, with emphasis on the exploration of the possible mechanisms of action and biological function of these atypical immunoglobulins, by means of specific biological probes. In contrast to immunoglobulins of B cell origins, atypical immunoglobulins were found to carry additional post-translational modifications, including a unique carbohydrate-associated epitope recognized by RP215 monoclonal antibody. This unique RP215-specific epitope enables us to differentiate between these two types of immunoglobulins. Atypical immunoglobulins expressed by cancer cells have been a common subject of interest in cancer immunology. Furthermore, the recent accumulation of experimental evidence has indicated that these atypical immunoglobulins are essential for the growth and proliferation of cancer cells under our normal immune environment. RP215 monoclonal antibody also reacts with many other cancer cell-expressed glycoproteins, known as CA215, on the cancer cell surface. Apoptosis of cultured cancer cells can be induced and growth inhibition of implanted tumors can be observed in nude mouse animal models. Therefore, humanized RP215 monoclonal antibody, which reacts mainly with surface bound CA215, may have the potential to be developed as an anti-cancer drug for the treatment of human cancers. A better understanding of cancer cell-expressed immunoglobulins not only improves our knowledge of cancer immunology, but also benefits cancer patients in the field of cancer monitoring and therapeutic treatments.

Keywords: RP215 Monoclonal Antibody, CDC and ADCC Reactions, Apoptosis

1. INTRODUCTION

It has been known for almost two decades that immunoglobulins can be expressed by human cells other than B cells (Cao et al., 1991; Chen et al., 2009; Hu et al., 2008; Kimoto, 1998; Yoshimi et al., 2002). Through the early studies of several investigators, it has been well documented that most cancer cells expressed immunoglobulins which were essential for their own growth and proliferation, either in vitro or in vivo (Li et al., 2004; Qiu et al., 2003). These observations have brought the attention of many researchers into the molecular mechanisms of action of cancer cell expressed immunoglobulins, as well as the potential benefit in employing this knowledge to create new therapeutic treatments for cancer patients.

In 1987, the monoclonal antibody (mAb), designated as RP215, was identified through immunization of mice with OC-3-VGH ovarian cancer cell extract followed by cell fusions and screening among three thousand hybridomas (Lee et al., 1992). RP215 mAb was later shown to react with glycoproteins, designated as CA215, through bindings with a unique RP215-specific carbohydrate-associated epitope (Lee et al., 2006). To
Therefore, more emphasis of this review will be placed regarding cancerous immunoglobulins in the field of immunology. During the last several years, a significant progress has been made regarding our current understanding in the expression and biological functions of atypical cancerous immunoglobulins (Lee et al., 2008). Through further protein Basic Local Alignment Search Tool (BLAST) analysis, it was concluded that the cancer cell derived CA215 glycoproteins consist mainly of immunoglobulin heavy chains, with a molecular size ranging from 50-75 kDa (Lee et al., 2006; 2008). Interestingly, RP215 mAb was shown to have no cross-reactivity with immunoglobulins of B cell origins (Lee et al., 2008). This would indicate that the expression of the CA215 epitope is highly linked with that of cancerous immunoglobulins only (Lee et al., 2008).

During the last decade, considerable interest has been on the expression of atypical immunoglobulins in the immunologically privileged sites of normal human tissues, including in the cells of the neurons, testes, eyes, placenta and breast. The etiology of immunoglobulins expressed by cancer cells was also actively pursued. In concise reviews in 2008 and 2009, early studies of immunoglobulins expressed in non-lymphoid lineage and neoplastic cells were reported, but with limited information regarding the etiology of cancerous immunoglobulins (Chen et al., 2009; Hu et al., 2008). During the last several years, a significant progress has been made regarding our current understanding in the expression and biological functions of atypical cancerous immunoglobulins (Chen et al., 2009; Hu et al., 2008). Therefore, more emphasis of this review will be placed on the implications of recent major developments regarding cancerous immunoglobulins in the field of cancer immunology (Chen et al., 2009).

1.1. Expression of Immunoglobulins by Normal and Cancer Cells in Humans

Since over a decade ago, numerous studies have demonstrated that immunoglobulins, or their heavy or light chain subunits, were expressed or detected in either non-lymphoid or cancer cells, in addition to their traditional origins from B cells (Babbage et al., 2006; Chen et al., 2009; Geng et al., 2007; Hu et al., 2008; 2003; Kimoto, 1998; Li et al., 2001; 2004; 2012; Okabe et al., 2001; Qiu et al., 2003; Yang et al., 2002; Zheng et al., 2007b; 2001; Zhu et al., 2008). In the case of normal human tissues, the majority of these atypical immunoglobulins were expressed or detected in tissues of the immune-privileged sites, such as the neurons, testes, eyes and placenta (Chen and Gu, 2007; Chen et al., 2009; Huang et al., 2008; 2009; Niu et al., 2011a; 2011b; Zhang et al., 2010; Zhao et al., 2011). Typically, Immunohistochemical (IHC) assays, Reverse Transcriptasepolymerase Chain Reaction (RT-PCR), in situ hybridization and Western blot assays were employed to detect the presence of immunoglobulins, or their fragments (heavy and/or light chains), in human tissues. In some cases, partial or total DNA or amino acid sequencing was performed to establish the identity of the detected immunoglobulins or their heavy or light chain fragments. In addition, RT-PCR was utilized as a tool to verify the gene expression of the heavy and light chains in these atypical immunoglobulins. Besides demonstrating the gene expression of immunoglobulins, the expression of essential genes necessary for the assembly of immunoglobulin genes, such as Recombinant Activating Gene (RAG1), Recombinant Activating Gene 2 (RAG2) and Activation-Induced cytidine Deaminase (AID) gene, were also documented in each case (Chen and Gu, 2007; Huang et al., 2008; 2009; Niu et al., 2011a; 2011b; Zhang et al., 2010; Zhao et al., 2011). However, in general, the mechanisms of action behind the expressions of these atypical immunoglobulins in normal human tissues were discussed with limited experimental evidence (Babbage et al., 2006; Chen and Gu, 2007; Geng et al., 2007; Hu et al., 2003; Huang et al., 2008; 2009; Li et al., 2001; Liu et al., 2009; Niu et al., 2011a; 2011b; Okabe et al., 2001; Yang et al., 2002; Zhang et al., 2010; Zhao et al., 2011; Zheng et al., 2007b; 2001; Zhu et al., 2008). In most cases, the expressions of the atypical immunoglobulins in the immunologically privileged sites of normal human tissues were found to only implement the possible functions of immune protection (Chen and Gu, 2007; Huang et al., 2008; 2009; Niu et al., 2011a; 2011b; Zhang et al., 2010; Zhao et al., 2011).

The expression of atypical immunoglobulins in various cancer cells or tissues continues to be the subject of major research interest. Besides cancer cells of epithelial cell origins, the majority of soft tissue tumors (Chen et al., 2010; Liu et al., 2012; Qiu et al., 2012b), such as sarcomas, were also found to express immunoglobulins, with the level of these atypical immunoglobulins correlating with markers of proliferation (PCNA, Ki67, cyclin D1) and tumor grades (Zhang et al., 2012). Based on the results of this study, it was concluded that the expression of atypical immunoglobulins was a common characteristic of all human cancers (Chen et al., 2009; Hu et al., 2008; Kimoto, 1998; Lee and Ge, 2009). Therefore, these atypical immunoglobulins can be considered as pan cancer biomarkers. However, it remains difficult to
differentiate the source of these atypical cancer immunoglobulins from that of normal lymphoid derived immunoglobulins in human tissues (Chen et al., 2009; Hu et al., 2008). Lymphocyte markers, such as CD19 and CD20, are required to rule out the cross contamination from lymphocyte infiltration as the source of immunoglobulins in cancer tissues (Chen et al., 2009; Hu et al., 2008; 2002).

A major breakthrough in research regarding cancer immunoglobulins came in 2008 when RP215 mAb was initially characterized with respect to its carbohydrate-associated epitope and the molecular identity of the corresponding glycoprotein antigens, CA215, was unfolded (Lee et al., 2008). Upon the initial MALDI-TOF MS analysis of CA215-derived tryptic peptides, it was generally concluded that RP215 mAb reacts with a carbohydrate-associated epitope of immunoglobulin heavy chains derived from cultured cancer cells. In contrast, RP215 mAb did not cross-react with immunoglobulins produced from normal B cells, indicating the complete absence of this RP215 specific epitope in normal lymphoid derived immunoglobulins (Lee et al., 2008). Thus, RP215 mAb and its recognized “sugar” epitope, marked a clear distinction between these two types of immunoglobulin molecules (Zheng et al., 2009; 2010).

1.2. Structural Characterization of Cancerous Immunoglobulins and the Etiology of Gene Expression

Since the initial observations that immunoglobulins were also expressed by non-haemopoietic cells (Cao et al., 1991; Chen et al., 2009; Hu et al., 2008; Kimoto, 1998), efforts have been made to elucidate the primary structures of the V-(D)-J gene rearrangement of expressed immunoglobulin heavy chains from cancer cells (Dudley et al., 2005; Early et al., 1980; Geng et al., 2003; Goebel et al., 2001; Jung et al., 2006; Zheng et al., 2007a). At the same time, the molecular mechanisms of cancerous immunoglobulin expressions were also compared with those from B cells. Generally speaking, expressions of atypical immunoglobulins in normal and cancer cells are quite distinct from those of B cell origins (Zheng et al., 2009; Zhu et al., 2010). In contrast to normal B cell derived immunoglobulins, cancerous immunoglobulins are expressed with limited but distinct somatic hypermutations in the V-(D)-J region of the heavy chain genes (Honjo et al., 2002; Muramatsu et al., 2000; Papavasiou and Schatz, 2002). In addition, in these cancerous immunoglobulins, no class switching mechanism was observed (Zheng et al., 2009; Zhu et al., 2010). The characteristics of the immunoglobulin heavy chain gene repertoire were investigated by sequencing of the VD junk region of the heavy chain genes. It was generally observed that seven predominant VHDHJH sets were derived from different cancer types. The mechanisms of limited hypermutation in cancer cells were found to be different from antigen selection in normal B cells. The promoter used for the gene expression of cancerous atypical immunoglobulins was also different from the promoter used for the gene expression of immunoglobulin by B cells (Oct. 2 vs. Oct. 1). Therefore, it was concluded that the cancer cell derived immunoglobulin genes may have a distinct repertoire, which may play a role in carcinogenesis (Zhu et al., 2010).

So far, experimental evidence seems to indicate that the cancer cell expressed immunoglobulins are essential for the growth and proliferation of cancer cells (Li et al., 2004; Qiu et al., 2003). Transfection of anti-sense DNA or siRNA to cancer cells resulted in growth inhibition of cancer cells in vitro (Li et al., 2012; Qiu et al., 2003). In addition, the sense and anti-sense siRNA were annealed and subcloned into the small hairpin RNA expression vector pSM2 as stable plasmids for transfection into cancer cells. Among the transformed cancer cells, siRNA mediated knockdown of cancerous immunoglobulins was observed by suppressing tumor growth in an immunodeficient nude mouse model in vivo and inhibiting the growth of cancer cells in vitro. It was hypothesized that cancerous immunoglobulins are capable of reducing Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) against the cancer cells by blocking the Natural Killer (NK) cells’ effector function through the Fc receptors of cancerous immunoglobulins (Iannello and Ahmad, 2005; Li et al., 2012; Winkel and Anderson, 1991). However, the ADCC-suppression mechanism has not yet been demonstrated to function in vivo since endogenous immunoglobulins derived from B cells might be dominant in the natural immune environment. Despite the ambiguity surrounding the functional mechanism of cancerous immunoglobulins, all the experimental observations have so far been consistent with cancer cell expressed immunoglobulins being a growth requirement and likely being regulated in an autocrine manner (Lee and Ge, 2010).

1.3. CA215 Vs. Cancerous Immunoglobulins

In-depth MALDI-TOF MS analysis was performed with tryptic peptides of affinity-purified CA215 from the shed medium of cultured OC-3-VGH cancer cells (Lee et al., 2008). It was further revealed that the cancer cells’ CA215 glycoproteins consist not only of immunoglobulin heavy chains, but also a number of other glycoproteins with suitable sites for unique
glycosylations to create a unique epitope that can be recognized by RP215 mAb (Lee et al., 2008; 2012e).
The details of such analyses are presented in Table 1. Besides immunoglobulins, the majority of identified CA215 glycoproteins could be grouped into the Immunoglobulin Superfamily (IgSF) proteins, as well as others. These IgSF proteins include T cell receptors, antigen presenting molecules, cell adhesion molecules and several others under the same category (Kimoto, 1998; Lee et al., 2012e).

As expected, it was found that in immunohistochemical staining studies of cancerous tissues, the positive staining patterns between RP215 and anti-immunoglobulins were not always identical (J. Gu, personal communication). However, the results of both immuno-probes demonstrated high correlation, since immunoglobulins are predominant and are common molecules recognized by these two immuno-probes. Both immuno-probes were shown to react with the soluble and membrane bound forms of immunoglobulins expressed by cancer cells (Lee et al., 2008). Therefore, RP215 mAb may be an acceptable alternative for study of cancerous immunoglobulins in the field of cancer immunology (Lee et al., 2008). Extensive evaluations and development processes on RP215 mAb are necessary in order to determine its biological effects on cancer cells and whether RP215 mAb can be developed as an anti-cancer drug in the future (Lee et al., 2009a; 2012a; 2012c).

1.4. Biological and Immunological Studies of RP215 Monoclonal Antibody and CA215

Through years of intensive studies, the molecular nature of CA215 and its mutual relationships with cancerous immunoglobulins have been somewhat established (Lee et al., 2008; 2012a; 2012e). This information is briefly summarized in the following sections in order to assess if RP215 mAb is a suitable candidate for development as an antibody-based anti-cancer drug, as well as to evaluate the potential role of CA215 in the immunology of cancer cells (Lee et al., 2012e).

1.5. Biochemical and Molecular Characterizations of RP215 mAb and CA215

Through biochemical analysis, it was generally established that RP215 mAb reacts specifically with a unique carbohydrate-associated epitope of cancerous CA215 glycoproteins consisting mainly of immunoglobulin heavy chains (Lee et al., 2008; 2012e). This was achieved by extensive MALDI-TOF MS analysis of CA215-derived tryptic peptides followed by the National Centre for Biotechnology Information (NCBI) protein BLAST services (Lee et al., 2012e). Through Western blot assay and IHC analysis, it was demonstrated that RP215 mAb reacts with almost all of the thirty established cancer cell lines (Table 2) (Lee et al., 2012e). This was consistent with RT-PCR and ELISA studies, which revealed the universal expressions of mRNA for the genes of immunoglobulin heavy and light chains, as well as the antigens, CA215 (Lee and Ge, 2009; Lee et al., 2012e). The mRNA expression of immunoglobulin-related genes was also demonstrated in selected cancer cell lines through semi-quantitative RT-PCR (Lee and Ge, 2009). In a given cancer cell line, OC-3-VGH (ovarian), these genes included those of the three different immunoglobulin classes (G, A and M) and subclasses (G1, G2 and G3), as well as the membrane domains of surface-bound immunoglobulins such as RAG1, RAG2 and AID. Interestingly, the mRNA expression ratios of different immunoglobulin classes or subclasses were discovered to be similar in the cancer cell lines to those in normal human serum specimens. Following single cell cloning of OC-3-VGH ovarian cancer cells, it was further revealed that IgG, IgM and IgA were co-expressed among cells originally derived from a single clone (Lee and Ge, 2009; Qiu et al., 2012a).

### Table 1. MALDI-TOF MS analysis of tryptic peptides derived from affinity-purified CA215

| Molecule Function/Category | Number of Peptides Matched | Total with homologyb |
|---------------------------|-----------------------------|----------------------|
| I. Antigen receptors      | 52 (42.0%)                  | 75/124 (60.5%)       |
| 1. Antibodies and immunoglobulins | 7 (5.7%)        |                      |
| 2. T cell receptor chains | 10 (8.1%)                  |                      |
| III. Adhesion molecules   | 12 (9.7%)                  |                      |
| IV. Cytokine and growth factors | 8 (6.5%)   |                      |
| V. Receptor tyrosine kinase/phosphatase | 7 (5.7%) |                      |
| VI. Others                | 9 (7.3%)                   |                      |

Obtained from (Lee et al., 2012c) with permission; a; Acid-eluded CA215 was used for MALDI-TOF MS analysis with ASCOT Program from http://matrixscience.com. b; Excluding overlapping peptides.
1.6. Immunoactivity of Cancerous Immunoglobulins Vs. Normal Immunoglobulins

To elucidate the molecular nature of cancerous immunoglobulins, the cancerous immunoglobulins were affinity-isolated from the shed medium of cultured cancer cells by sequential purifications with RP215-linked and anti-human IgG-linked immunoaffinity chromatography. The resulting purified cancerous Immunoglobulins (IgG) were characterized biochemically and immunologically (Lee et al., 2012b).

By using typical EIA kit for normal human IgG, it was observed that cancerous IgG exhibited a significantly lower immunoactivity than that of normal IgG (1-5% of the normal activity) (Lee et al., 2012b). This phenomenon can only be explained based on the fact that atypical cancerous immunoglobulins are aberrantly glycosylated, resulting in significant alterations in protein structures and immunoactivities of the former. This observation was consistent with an earlier report by other scientists regarding the heterogeneity arising from aberrant immunoglobulin expression in cancer cells (Hu et al., 2011).

Table 2. Expressions of human immunoglobulin heavy chain (or CA215) and light chains in different fibroblast and cancer cell lines as detected by Western blot, EIA and RT-PCR

| Origins      | Designation cell line | ATCC No. | Methods Used<sup>d</sup> (Relative Signal Strength<sup>c</sup>) | I (Hc) | II Hc | Hc | l/k |
|--------------|-----------------------|----------|---------------------------------------------------------------|--------|------|----|-----|
| Breast       | MCF7<sup>d</sup>      | HTB-22   | +                                                             | +      |      | +  | +  |
|              | MDA-MB-231<sup>d</sup> | HTB-26   | +                                                             | +      |      | +  | +  |
|              | MDA-MB-468            | HTB-132  | +                                                             | -      |      | +  | +  |
|              | T-47D<sup>d</sup>     | HTB-133  | +                                                             | ±      |      | +  | ±  |
| Cervical     | C-33A                 | HTB-31   | +                                                             | +      |      | +  | +  |
|              | CA33                  | HTB-35   | +, ±                                                         | +      |      | +  | +  |
|              | SiHa                  | HTB-33   | +                                                             | +      |      | +  | +  |
| Colorectal   | HT-115                | CCL-247  | +                                                             | ±      |      | +  | ±  |
|              | HCT-116               | HTB-38   | +                                                             | ±      |      | +  | +  |
|              | SW-48<sup>d</sup>     | CCL-231  | +                                                             | ±      |      | +  | +  |
| Hepatocellular | Hep3B               | HB-8064  | +                                                             | ±      |      | +  | ±  |
|              | HepG2                 | HB-8065  | +                                                             | +      |      | +  | +  |
|              | Hep-2                 | HTB-133  | +                                                             | +      |      | +  | +  |
| Kidney       | 293<sup>d</sup>       | +       | +                                                             | +      |      | +  | +  |
| Lung         | A549<sup>d</sup>      | CCL-185  | +                                                             | ±      |      | +  | ±  |
|              | Calu-6                | HTB-56   | +                                                             | ±      |      | +  | +  |
|              | H441                  | HTB-174  | +                                                             | ±      |      | +  | +  |
|              | H460                  | +       | +                                                             | +      |      | +  | +  |
| Lymphoma     | HEL1                  | ±       | ±                                                             | ±      |      | ±  | ±  |
| Melanoma     | MMAN                  | ±       | ±                                                             | ±      |      | ±  | ±  |
|              | MMRI                  | +       | ±                                                             | +      |      | +  | +  |
| Neuroblastoma| SH-SY5Y               | CRL-2266 | +                                                             | ±      |      | ±  | ±  |
| Osteosarcoma | U-2 OS                | HTB-96   | +                                                             | ±      |      | +  | ±  |
| Ovarian      | SK-OV-3               | HTB-77   | +                                                             | ±      |      | +  | ±  |
|              | OC-3-VGH              | +       | ±                                                             | +      |      | +  | +  |
| Placenta     | JEG-3                 | HTB-36   | +, ±                                                         | ±      |      | ±  | ±  |
| Prostate     | DU 145<sup>d</sup>    | HTB-81   | +                                                             | ±      |      | +  | ±  |
|              | PC-3                  | CRL-1435 | +                                                             | ±      |      | +  | ±  |

Obtained from (Lee and Ge, 2009) with permission. a; Normal hyperplastic and proliferated fibroblast cell lines derived from fetal lung tissue. b; Methods: Method I: Western blot using RP215, goat anti-human IgG, COX-100 (Mouse anti-human IgG heavy chain), or goat anti-human IgG (λ/κ) as a probe. Method II: EIA using coated cells and RP215 or COX-100 as a probe. Method III: RT-PCR using primers for immunoglobulin heavy chain constant region or light chain constant region Igλ and/or Igκ under the same conditions. Detailed conditions are described in the text. c; The strength of the signal in the order of + (strong), ± (weak), - (invisible). d; IgG was observed in these cell lines from the following publications: (Babbage et al., 2006; Chen and Gu, 2007; Lee et al., 2008; Qiu et al., 2003). e; Western blot exhibited a positive band when using anti-human IgG as a probe but showed no band when using RP215 as a probe.
Table 3: The TUNEL apoptosis assay to demonstrate the increase in apoptosis of cultured cancer cells from prostate, lung, cervix, breast and ovary, respectively in response to 24-48 hrs of treatment with various antibodies.

| Cancer cell Line (tissue) | Incubation time (hrs) | Antibody | Antibody Concentration (µg/mL) | % Apoptosis (Negative Control)* |
|--------------------------|-----------------------|----------|-------------------------------|---------------------------------|
| PC-3 (prostate)          | 48                    | RP215    | 10                            | 31±7 (9±1)*                     |
|                          |                       | ChRP215  | 10                            | 38±5 (9±1)**                    |
|                          |                       | Goat anti-human IgG | 10 | 36±4 (9±1)*                    |
| DU-145 (prostate)        | 24                    | RP215    | 10                            | 32±7 (12±3)*                    |
|                          |                       | Goat anti-human IgG | 10 | 46±8 (12±3)*                    |
|                          |                       | RP215    | 10                            | 35±8 (10±1)*                    |
|                          |                       |          | 20                            | 43±7 (7±2)*                     |
| A549 (lung)              | 24                    | RP215    | 10                            | 46±9 (12±3)*                    |
|                          |                       | Goat anti-human IgG | 10 | 30±9 (11±5)*                    |
|                          |                       |          | 20                            | 36±12 (17±3)*                   |
|                          |                       |          | 20                            | 36±10 (12±3)*                   |
| C33A (cervix)            | 24                    | RP215    | 10                            | 58±11 (20±3)*                   |
| MDA-MB-435 (breast)      | 24                    | RP215    | 20                            | 37±8 (6±1)**                    |
|                          |                       | Goat anti-human IgG | 10 | 44±4 (7±2)**                    |
|                          |                       | RP215    | 20                            | 43±8 (8±3)**                    |
| OC-3-VGH (ovary)         | 24                    | RP215    | 10                            | 48±5 (8±3)**                    |
|                          |                       | RCA104   | 1                             | 51±12 (18±2)                    |
|                          |                       | RCA111   | 1                             | 35±3 (6±2)                      |
|                          |                       | RP215    | 1                             | 38±4 (6±2)**                    |
|                          |                       |          | 1                             | 43±5 (6±2)**                    |

Modified from (Lee et al., 2012a) with permission. *Single asterisk (*) and double asterisks (**) indicate a statistical significance of p<0.05 and p<0.01, respectively.

1.7. Effect of RP215 mAb on the Induction of Apoptosis of Cancer Cells

By using terminal deoxynucleotidyl transferase dUTP Nick End Labeling (TUNEL) assay, it was clearly demonstrated that RP215 MAb incubated at a concentration of 1-10 µg mL⁻¹ for 24-48 h could induce apoptosis of cultured cancer cells, including those from the ovary, cervix, breast, lung and prostate (Lee and Ge, 2010). The chimeric forms of RP215, ChRP215, were found to have the same effects as that of murine RP215. In addition to RP215, apoptosis could also be induced in OC-3-VGH ovarian cancer cells by other RP215-epitope-related monoclonal antibodies (RCA10, RCA100, RCA104, RCA110 and RCA111 to be described later) (Lee et al., 2012d). By comparison, goat anti-human IgG also induced apoptosis to a similar extent to that of RP215 mAb, indicating that cancer cell expressed surface bound immunoglobulins are effectively blocked by antibodies against cancerous immunoglobulins (Lee and Ge, 2010; Lee et al., 2012d). The results of the apoptosis assay are summarized in Table 3 for comparison.

1.8. Effect of RP215 mAb on Complement-Dependent Cytotoxicity of Cancer Cells

The Complement-Dependent Cytotoxicity (CDC) assay was employed to study the complement-dependent cell lysis to cultured cancer cells in the presence of complement and...
RP215 mAb (10 µg mL⁻¹, 2 h of incubation at 37°C), ChRP215 also demonstrated a similar degree of CDC reaction to cultured cancer cells under the same conditions of incubation (Lee et al., 2012a; 2012c; 2012e). Goat anti-human IgG were also found to have similar effects to those of RP215 mAb. This suggested that CDC reactions are induced in the presence of complement to the surface bound immunoglobulins by antibodies, RP215 and goat anti-human IgG. In contrast, complement alone revealed little or no effect on CDC reactions to cultured cancer cells. The effects of specific cell lysis by CDC assays are summarized in Fig. 1.

1.9. Effects of RP215 mAb on the Expression of Selected Genes in Cultured Cancer Cells

Through studies of gene regulations by quantitative and semi-quantitative RT-PCR, a number of genes related to the growth of cancer cells were examined for their response to the treatments of cultured cancer cells with RP215 mAb for 48 h. The results of this qualitative analysis with a number of selected genes were summarized for assessment. It was generally concluded that RP215 mAb was found to up-regulate the gene expression of IgG and NFK-B1, but significantly down-regulate genes of the ribosomal proteins, Po, P1 and P2. These genes are essential for protein synthesis in cultured cancer cells (Lee et al., 2012c).

RP215 incubation with cultured cancer cells was found to have little effect on Epidermal Growth Factor (EGF), but caused a significant decrease in the gene regulation of c-fos oncogene (Lee et al., 2012c). RP215 was also found to down-regulate several genes which are essential for cell cycle regulations, such as p21 and cyclin D.
Based on the results of the gene regulation studies, it can be shown that the molecular mechanism, by which apoptosis of cultured cancer cells is induced, is consistent with the hypothesis that self-expressed cancerous immunoglobulins are essential growth factors for the survival of the cancer cell (Lee et al., 2012a; 2012c).

1.10. “Proof of Concept” Nude Mouse Experiments with RP215 mAb

Judging from the effect of RP215 mAb on inducing apoptosis and CDC reactions of cultured cancer cells, it is apparent that CA215 on the surface of cancer cells might be a suitable target for RP215 mAb. “Proof of concept” nude mouse experiments were performed with the implant of tumor cells from three different cancer cell lines, namely OC-3-VGH (ovary), SK-MES-1 (lung) and C33A (cervix) (Lee et al., 2009a; 2012a; 2012c). With some differences in experimental design, significant dose-dependent tumor reduction or tumor growth inhibition was observed in each case (Lee et al., 2012a). Typical results are summarized in histograms for each cancer line model, including detailed statistical analysis. These are presented in Fig. 2 for comparisons.

1.11. Anti-Idiotypic Monoclonal Antibodies of RP215 mAb as Anti-Cancer Vaccines and Immunodominant Epitope

RP215 mAb was demonstrated to react with the unique carbohydrate-associated epitope of CA215 glycoproteins identified in many cancer cells (Lee et al., 2006; 2008). Anti-idiotype (aid) monoclonal antibodies can be generated in rats against the Fab-idiotype domains of RP215. The anti-idiotypic monoclonal antibodies were found to bear the internal images of the RP215-associated epitope (Lee et al., 2010; Lee and Ge, 2010). To further characterize the anti-idiotypic monoclonal antibodies, mice were immunized to generate Ab3 (anti-aid). By means of TUNEL assay, Ab3 obtained from mouse immune sera was found to induce apoptosis to cultured cancer cells, similar to that of RP215 mAb. Through Western blot assay, Ab3 antisera and RP215 mAb were found to react with the same protein bands (50-75 kDa) from cancer cell extract, corresponding to those of immunoglobulin heavy chains. By immunohistochemical staining, the majority of cancer cells from different tissue origins were positively stained by both Ab3 antisera and RP215. These experimental observations strongly support the concept that rat anti-idiotypic mAb or its Fab fragments bear the internal images of the RP215-specific epitope (Lee et al., 2010). These anti-idiotypic mAbs may be suitable as anti-cancer vaccines which are capable of inducing Ab3 responses in humans to prevent or potentially treat cancer.

During our early studies, additional new monoclonal antibodies were generated against affinity-purified CA215 as immunogens. Unexpectedly, all of the new generation monoclonal antibodies (RCA-related mAbs) recovered were found to react with epitope(s) related to the one recognized by RP215 mAb (Lee et al., 2012d). This indicated the existence of an immunodominant carbohydrate-associated epitope recognized originally by RP215 mAb in mice.

Therefore, among the second generation mAbs, two (RCA10 and RCA100) were found to have identical amino acid sequences as those of RP215 and react with the linear structure of the RP215 epitope. The other three (RCA104, RCA110 and RCA111) were considered to react only with conformational domains of the same epitope. RP215 and its RCA related mAbs were shown to react with the same linear or conformational carbohydrate associated epitope(s). This could be demonstrated either by self-pairing or mutual pairing of any of these mAbs in enzyme immunoassays for quantitative determinations for CA215 (Lee et al., 2012d). The reason for the existence of immunodominant epitope(s) recognized by RP215 and other CA215-derived mAbs in mice remains to be explained (Lee et al., 2012d).

1.12. CA215 and Expression of Immunoglobulin Superfamily Proteins by Cancer Cells

During the initial analysis of tryptic peptides of CA215, it was revealed that over 40% of peptide fragments were homologous to that of immunoglobulin heavy chains (Table 1). When other non-immunoglobulin-related peptides were analyzed by NCBI protein BLAST services, as many as 60% of the peptides from CA215 were found to consist mainly of non-immunoglobulin-related peptides. By NCBI protein BLAST services, as many as 60% of the peptides from CA215 were found to consist mainly of non-immunoglobulin-related peptides, as many as 60% of the peptides from CA215 were found to consist mainly of non-immunoglobulin-related peptides. To investigate if T-cell receptors are widespread among cancer cells, semi-quantitative RT-PCR was performed with the cell extract of over twenty cancer cell lines (Lee et al., 2012e). The results showed that as many as 80% of these cancer cells expressed T-cell receptors (α and β subunits). It was revealed that as many as 80% of these cancer cells expressed T-cell receptors (α and β subunits), but none were found to express significant levels of co-receptors or co-stimulators, such as CD3, CD4 and CD8. These observations suggested that cancerous T-cell receptors are non-functional, compared to normal T-cells in humans (Lee et al., 2012e). In addition, several cell
adhesion molecules with IgSF characters, including CD47, CD54, CD58 and CD147, were found to be highly expressed among all cancer cell lines (Lee et al., 2012e). Results of such expression analysis are presented in Table 4. Antibodies against cell receptors were found to induce apoptosis and CDC to cultured OC-3-VGH ovarian cancer cells, similar to those of RP215 MAb (Fig. 3). Based on the results of this study, it can be concluded that RP215 mAb affects not only the surface bound immunoglobulins of cancer cells, but also the T cell receptor α or β chains and other IgSF proteins as well (Lee et al., 2012e). Widespread expressions of nonfunctional T-cell receptors among cancer cells may have implications in cancer immunotherapy via T-cell activation strategy, as well as induced tolerance of T-cells to tumor-associated antigens in humans (Weber, 2007; Witherden et al., 2010).

1.13. Glycoanalysis and Glycosylation Site Mapping of RP215-Specific Carbohydrate-Associated Epitope in CA215

Attempts were made to elucidate the possible sugar structure of the carbohydrate-associated epitope(s) recognized by RP215 detected in CA215 (Lee and Azadi, 2012). The affinity-purified CA215 from both OC-3-VGH ovarian and C33A cervical cancer cell lines was subjected to glycoanalysis. Profiles of N-linked and O-linked glycans were analyzed and compared with those of known glycoproteins. In the case of N-linked glycans, CA215 was found to contain high mannose and complex bisecting structures with terminal N-glycolyneuraminic acid, when compared with those of normal human immunoglobulins. For O-linked glycans, several oligosaccharides were detected in CA215 with structures similar to those of mucins, but also with terminal N-glycolyneuraminic acid.

These results are presented in Table 5. To further identify the molecular nature of glycoproteins with linked RP215-specific epitope, glycosylation site mappings of CA215 were performed. From the results of a total ten glycopeptides isolated, two were found to be N-linked and eight O-linked. Protein BLAST search of peptide sequence homology revealed that two N-linked and six O-linked glycopeptides were almost 100% matched to human immunoglobulin heavy chains. The results of one such glycosylation site mapping are summarized in Table 6.

Based on this analysis, it can be suggested that immunoglobulin heavy chains could be the main sites for the attachment of the RP215-specific carbohydrate-epitope. N-glycolyneuraminic might not be directly involved in the RP215-epitope recognition. Based on the results of this glycoanalysis, it can be suggested that the RP215-specific epitope is composed of O-linked glycans of simple oligosaccharides, which are located mainly on the variable regions of the cancerous immunoglobulins (CA215D is designated as affinity-purified cancerous IgG in Table 5) (Lee and Azadi, 2012). In contrast, O-linked glycans have never been identified in normal human IgG (Arnold et al., 2007).

![Fig. 3](image_url)

Fig. 3. (A) The Complement Dependent Cytotoxicity (CDC) assay to demonstrate the induction by anti-T cell receptor β subunit (TCRβ) MAb, RP215 and goat anti-human IgG to OC-3-VGH. Lane 1: complement only. Lane 2: normal mouse IgG (NM1gG). Lane 3: NM1gG and complement. Lane 4: anti-TCRβ MAb. Lane 5: anti-TCRβ MAb plus complement. Lane 6: RP215. Lane 7: RP215 plus complement. Lane 7: goat anti-human IgG (GαHIGG). Lane 8: GαHIGG plus complement. Double asterisks indicate statistical significance of p<0.01. Both A and B were modified from (Lee et al., 2012e) with permission. (B) The TUNEL apoptosis assay to demonstrate the increase in apoptosis of cultured OC-3-VGH cancer cells in response to treatment for 48 antibodies with the following antibodies (10 µg mL⁻¹): lane 1: NM1gG, lane 2: anti-human IgM, lane 3: anti-human IgG, lane 4: RP215, lane 5: normal rabbit IgG, lane 6: rabbit anti-T Cell Receptor β subunit peptide 1 (TCRβ1) and lane 7: rabbit anti-T Cell Receptor β subunit peptide 2 (TCRβ2). Single asterisk and double asterisks indicate statistical significance of p<0.05 and p<0.01, respectively. Both A and B were modified from (Lee et al., 2012e) with permission.
Table 4. Expression of human T Cell Receptor (TCR), IgG and selected CD markers in different cancer cells and two fibroblast cell lines, as detected by RT-PCR.

| Origin            | Designation  | ATCC No. | TCR (α) | TCR (β) | IgG (Fc) | CD3 | CD4 | CD8 | Cell Adhesion Molecules |
|-------------------|--------------|----------|---------|---------|----------|-----|-----|-----|------------------------|
| Breast            | MDA-MB-231   | HTB-26   | +++±    | +++±    | +        | -   | -   | -   | +                     |
| Cervical          | C-33A        |          | +       | +       | ±        | -   | -   | -   | +                     |
| Colorectal        | HCT115       | CCL-231  | -       | ±±      | -        | -   | -   | -   | +                     |
|                   | SW-48        | HTB-29   |         | ±±      | -±      | -   | -   | -   | +                     |
| Hepatocellular    | Hep3B        | HB-8064  | ++      | +       | -±      | -   | -   | -   | +                     |
| Lung              | Calu-6       | HTB-56   | +++     | +       | -±      | -   | -   | -   | +                     |
|                   | H441         | HTB-174  | ++      | +       | -±      | -   | -   | -   | +                     |
|                   | WI-38d       | CCL-75   | +++     | +±      | -±      | -   | -   | -   | +                     |
|                   | A549         | CCL-185  | ±±      | -       | -±      | -   | -   | -   | +                     |
|                   | MRC-5d       | CCL-171  | ±±      | -       | -±      | -   | -   | -   | +                     |
|                   |              |          |         |         |         |     |     |     |                       |
| Lymphoma          |              |          |         |         |         |     |     |     |                       |
|                   | Raji         | CCL-86   | +++±    | +++±    | +±      | -   | -   | -   | +                     |
| Melanoma          | MMRU         |          | ++      | -       | +±      | -   | -   | -   | +                     |
| Ovarian           | SKOV-3       | HTB-77   | +++     | +       | -±      | -   | -   | -   | +                     |
|                   | OVCAR-3      |          | +       | ±±      | -±      | -   | -   | -   | +                     |
|                   | OC-3-VGH     |          | +±      | ++      | -±      | -   | -   | -   | +                     |
| Prostate          | Du 145       | HTB-81   | +±      | +±      | -±      | -   | -   | -   | +                     |
| T-cell leukemia   | Jurkat       | TIB-152  | +++     | +++     | +±      | -   | -   | -   | +                     |
| Bone marrow       | K562         | CCL-243  | +±      | +±      | -±      | -   | -   | -   | +                     |

Obtained from (Lee et al., 2012c) with permission. a: As a positive control, human peripheral blood cells showed expression of CD3, CD4 and CD8. b: All the cell adhesion molecules including CD47, CD54, CD58 and CD147 expressed among all the cancer cell lines listed. c: Relative expression level follows the order of +++ (strong positive), ++, +,±(very weak), -(negative). d: Normal hyperplastic and proliferated fibroblast cell lines derived from fetal lung tissue.

Table 5. Comparative profiles of permethylated O-linked glycans of human IgG and five different CA215 samples.

| Sample ID       | Observed Mass m/z [M+Na]+ | Proposed structure | Structure |
|-----------------|---------------------------|--------------------|-----------|
| CA215 (lots: A, B and C) a | 534 | GalNAc1Gal1 | ![Structure](CA215_A_B_C.png) |
| CA215 (lots: A and B) | 708 | GalNAc1Gal1Fuc1 | ![Structure](CA215_A_B.png) |
| CA215 (lots: A, B, D, C, E and F) b | 896 | GalNAc1Gal1NeuAc1 | ![Structure](CA215_A_B_D_C_E_F.png) |
| CA215 (lots: C, E and F) | 926 | GalNAc1Gal1NeuGc1 | ![Structure](CA215_C_E_F.png) |
| CA215C | 940c | GalNAc1GlcNAc1NeuAc1 | ![Structure](CA215C.png) |
| CA215 (lots: A, B and C) | 1140 | GalNAc1GlcNAc1Gal1NeuAc1 | ![Structure](CA215_A_B_C.png) |
| CA215 (lots: C, D, E and F) | 1257 | GalNAc1Gal1NeuAc2 | ![Structure](CA215_C_D_E_F.png) |
| CA215 (lots: C, E and F) | 1317 | GalNAc1Gal1NeuGc2 | ![Structure](CA215_C_E_F.png) |
| CA215 (lots: A, B, C, E and F) | 1345 | GalNAc1GlcNAc1Gal2NeuAc1 | ![Structure](CA215_A_B_C_E_F.png) |
| CA215 (lots: C, E and F) | 1375 | GalNAc1GlcNAc1Gal2NeuGc1 | ![Structure](CA215_C_E_F.png) |

Obtained from (Lee and Azadi, 2012) with permission. a: CA215 lots A, B and C were from OC-3-VGH ovarian cancer cells (CA215-OC-3) lots A and B were obtained through acid elution, whereas lots C, D, E and F were obtained through elution with 3M urea. b: Lot CA215D was obtained by an additional purification of urea-eluted CA215 (S15K-100425) with goat anti-human IgG affinity column followed by the same analysis. CA215D is designated as affinity-purified cancerous IgG). CA215 lots E and F were from C-33A cervical cancer cells (CA215-C33A). c: Detected by MALDI-TOF MS method but not found by NSI-MS method. d: N-acetylgalactosamine (□), N-acetylglucosamine (■), Fucose (▲), Galactose (●), N- acetylneuraminic acid (♦) and N-glycolylneuraminic acid (♣)
A number of experimental observations have been documented to indicate that RP215-specific epitope is carbohydrate-associated in CA215 (Lee and Azadi, 2012). Initially it was observed that RP215 immunoactivity was decreased significantly upon treatments with mild periodate at neutral pH, or high temperatures (100°C, 15 minutes), or at extreme pH (< 2 or < 12.0) (Lee et al., 2006; Lee and Ge, 2010). Culture of cancer cells in serum-free medium also resulted in a total loss of RP215 immunoactivity (Lee et al., 2010). On the other hand, the deduced amino acid sequences of Fc regions of cancerous immunoglobulins (IgG or IgA) were shown to be almost identical to those of normal human immunoglobulins (Lee and Ge, 2009). This would suggest that RP215-specific epitope is carbohydrate but not peptide structure-associated. Furthermore, RP215-epitope(s) were detected in many other unrelated proteins with no mutual homology in their respective amino acid sequences (Lee et al., 2012e). Finally, aberrant glycosylations of cancerous immunoglobulins could result in the creations of RP215-associated “sugar” epitope and low immunoactivity when compared to those of normal human immunoglobulins (Lee et al., 2012b).

1.14. RP215-Based Enzyme Immunoassays and Clinical Diagnostic Applications

Judging from the molecular and epitope nature, CA215 should be considered as pan-cancer bio-markers. In view of the existence of multiple RP215-specific sugar epitopes, RP215 alone can be used for sandwich immunoassays for determination of shed or soluble forms of CA215. Therefore, serum levels of CA215 can be determined quantitatively for diagnostics and monitoring of human cancer derived from different tissue origins (Lee, 2009). Patient serum specimens with confirmed cancer diagnosis were subject to analysis by enzyme immunoassays. Normal human serum specimens were used as the negative control for comparative studies. Results of such analysis with more than 500 serum specimens from patients of over ten different cancers are presented as a scattergram in Fig. 4. Based on the results of such analysis, the positive rates vary significantly with different types of cancers and also levels among individuals with the same type of cancer. Further in-depth analysis with serum specimens of ovarian and cervical cancers was performed to assess the clinical diagnostic utility of CA215 as pan-cancer bio-markers (Lee, 2009; Lee et al., 2009b). It was generally established that serum CA215 levels are well correlated with the cancer staging of patients under consideration (Lee, 2009). Furthermore, the tumor burden of a given cancer patient can also be reflected from the serum CA215 levels, as radiation and surgical operations could significantly reduce the serum level of CA215 in cancer patients after one week (Lee, 2009; Lee et al., 2009b).

### Table 6. N-linked and O-linked glycosylation site mappings of CA215

| Accession number | Peptide detected | Peptide sequence homology of proteins (%) |
|------------------|------------------|------------------------------------------|
| I. CAC12842.1    | 1. EEQFNSTFR     | Immunoglobulin heavy chain (Fc) (100%)   |
| II. CAA04843.1   | 2. EEQFNSTYR     | Immunoglobulin heavy chain (Fc) (100%)   |
| III. AAB60643.2  | 3. LSVFTSEWQR    | Cathepsin S (100%)                       |
| IV. AAK6890.1    | 4. FCLATNADGDSSK | Hemicentin (100%)                        |
| V. AAD38158.1    | 5. DTLMISR       | Titin (100%)                             |
| VI. AAC39746.2   | 6. GYLPEPVTVTWNSGTNVR | Immunoglobulin heavy chain (Fc) (100%)   |
| VII. AAN76042.1  | 7. SVSTLCMINGFYPSIDISVEWEK | Immunoglobulin heavy chain (Fc) (90%) |
| VIII. CAJ75462.1 | 8. QSGLYSLSSVSVTSSQPVTNCNV | Immunoglobulin heavy chain (Fab and Fc) (100%) |
| IX. AAB74486.2   | 9. VYTMGPPREELSSR | Immunoglobulin heavy chain (Fc) (98%)   |
| X. NP_001139647.1| 10. TFPSSVR      | IgA variable region (89%)                |

Obtained from (Lee et al., 2012e) with permission. a; Bold letters indicate glycosylation sites.
As a pan-cancer bio-marker, CA215 can be used in combination with more tissue-specific cancer markers for a better clinical diagnosis (Lee et al., 2009b). For example, in the case of ovarian cancer, the combined use of CA215 and CA125 could significantly improve the detection diagnostic sensitivity. Similarly, Alpha Fetoprotein (AFP) and CA215 can be combined for a better diagnosis of hepatoma as the detection rate of using both cancer markers is higher than that of a single cancer marker (Lee et al., 2009b; Park et al., 2011).

To further document that CA215 can be a useful serum pan-cancer bio-marker, Western blot assay was employed to detect cancerous immunoglobulins from cancer patients with high serum levels of CA215. These cancer patient serum specimens included those of the esophagus, stomach, breast, colon and liver. With RP215 as the unique probe, cancerous immunoglobulins (mainly IgG) from these serum specimens can be unambiguously detected by observed proteins bands with a molecular weight of 160 kDa for intact IgG and 50-55 kDa for IgG heavy chain subunits (Lee et al., 2009b). The results of this analysis enabled us to make a close link between CA215 and cancerous immunoglobulins (Lee et al., 2009b).

1.15. Applications of RP215 mAb for the Clinical Status Assessment of Cancer Cells in Humans

RP215 mAb reacts specifically with the unique “sugar” epitope of cancer cell-expressed CA215, such as a variety of IgSF proteins, including cell adhesion molecules. Bindings of RP215 on these IgSF proteins might affect the proliferation and migration (metastasis) of cancer cells in vivo (Barclay, 2003; Lee et al., 2012e). Expressions of RP215-specific epitope were found to be well correlated with the status of cancer cells and cancer stem cells. Higher expressions of RP215 epitope seem to take place in the metastatic states of cancer cells (Qiu et al., 2012a) than those of cancer in situ. Therefore, it is reasonable to hypothesize that RP215 mAb can be used as a diagnostic tool to study the clinical status of cancer cells in terms of their potential for proliferation, migrations and prognosis in vivo.

1.16. Assessment of RP215 Monoclonal Antibody as Anti-Cancer Drugs

Although not completely understood, it is generally accepted based on experimental evidence that cancerous immunoglobulins are essential for the growth and proliferation of cancer cells in vitro or in vivo. RP215 mAb recognizes unique “sugar” epitopes of cancer cell-surface expressed CA215 glycoproteins, which consist mainly of cancerous immunoglobulins plus other minor IgSF components. Therefore, it is reasonable to assume that RP215 mAb can be used to target cancer cells by inducing apoptosis, CDC and ADCC reactions in vivo upon antibody binding on the cell surface. Biological and immunological studies summarized in this review may provide meaningful information and “proof of concept” regarding the suitability of humanized RP215 mAb as an anti-cancer drug in humans.

Since most atypical immunoglobulins with RP215-specific epitope were found in immune privileged
sites of normal human tissues, such as the neuron, testes, eyes and placenta (Chen et al., 2009; Hu et al., 2008). Therefore, infusion of humanized RP215 mAb may not be toxic to the human body. On the contrary, human cancerous tissues may be preferentially targeted due to abundant expressions of RP215-specific epitope on the cancer cell surface.

2. CONCLUSION

2.1. Implications of Cancerous Immunoglobulins and Ca215 To Cancer Immunology

Universal expressions of atypical immunoglobulins by cancer cells of different tissue origins should be generally accepted in cancer research, even though the etiology is unknown (Chen et al., 2009; Hu et al., 2008). With the identification of RP215-specific carbohydrate-associated epitope, more information about the immunology of cancer cells was unfolded (Lee et al., 2008; 2012e). Surface bound CA215 glycoproteins expressed by all cancer cells consist not only of immunoglobulins, but also a number of immunoglobulin Superfamily (IgSF) proteins, including T cell receptors, MHCI and MHCII molecules, cell adhesion molecules, as well as cytokine receptors (Lee et al., 2012e). The characteristic secondary domain structures of IgSF proteins enable the additional glycosylations of this specific group of molecules in cancer cells (Barclay, 2003), leading to the additional unique glycosylated epitope recognized by RP215 mAb. Besides the surface bound immunoglobulin molecules, other IgSF proteins can also be targeted by this RP215 mAb to induce apoptosis of cancer cells. Furthermore, CDC and ADCC reactions are also common and effective in the immunotherapy of cancer cells in vivo.

During the extensive molecular analysis of cancer cell expression of CA215 with the unique RP215 specific epitope, many glycoproteins involved in the normal immune system were identified and found to be highly expressed among many types of cancer cells, but rarely found in non-immune related cells in humans. Functional significance of these IgSF proteins remains to be explored (Barclay, 2003). It remains to be established if the immunoglobulins play any significant roles in the innate immunity of cancer cells (O’Neill, 2008; So and Ouchi, 2010). The widespread expression of T cell receptors in cancer cells should be addressed in relation to the T cell activation and/or T cell tolerance in cancer immunotherapy (Witherden et al., 2010). Finally, the high expression of IgSF-related cell adhesion molecules may be related to the metastasis of cancer cells. Some of these puzzles may have to be resolved for further understanding of cancer immunology, as well as for the effective cancer immunotherapy in humans (Weber, 2007). The preferential attachment of the RP215-specific epitope to cancer cell-expressed CA215 glycoproteins but not the same proteins in the majority of normal cells remains to be investigated (Lee et al., 2008; 2012c).

We believe that the unique RP215-specific epitope(s) arises from the aberrant expressions of certain glycoloy transferases among all cancer cells. This question can be answered only when the epitope structures and enzymes involved in the “sugar” attachment (Lee and Azadi, 2012) have been fully elucidated.

Despite a significant advancement regarding our understanding of cancerous atypical immunoglobulins, their general and special roles in the growth and proliferation of cancer cells, as well as their molecular evolutionary origins, remains to be elucidated. Additional experimental and clinical studies would be required to address these questions. Nevertheless, a better understanding of cancerous immunoglobulins and CA215 will not only improve our knowledge in the field of cancer immunology but also benefit cancer patients in the area of cancer monitoring and therapeutic treatments.

3. ACKNOWLEDGEMENT

The researchers wishes to acknowledge the helpful discussions with the following scientists in China regarding the research progress of cancerous immunoglobulins: Dr. Jiang Gu (Shantou University, Shantou, Guangdong), Dr. Xiayan Qiu (Peking University, Beijing) and Dr. Ya Cao (Central South University, Changsha, Hunan). The editorial contributions and discussions of Suefay Liu and Dr. Bixia Ge to the content of this publication are also acknowledged. This work was supported in parts by the Canadian NSERC-IRAP (#743918) and Vancouver Biotech Ltd.

3.1. Conflict of Interest

Gregory Lee is cofounder of Vancouver Biotech Ltd. For the remaining authors, none are declared.

4. REFERENCES

Arnold, J.N., M.R. Wormald, R.B. Sim, P.M. Rudd and R.A. Dwek, 2007. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol., 25: 21-50. DOI: 10.1146/annurev.immunol.25.022106.141702

Babbage, G., C.H. Ottensmeier, J. Blaydes, F.K. Stevenson and S. Sahota, 2006. Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines. Cancer Res., 66: 3996-4000. DOI: 10.1158/0008-5472.CAN-05-3704
Barclay, A.N., 2003. Membrane proteins with immunoglobulin-like domains-a master superfamily of interaction molecules. Semin. Immunol., 15: 215-223. DOI: 10.1016/s1044-5323(03)00047-2

Cao, Y., Y. Sun, S. Poirier, D. Winterstein and G. Hegamyer et al., 1991. Isolation and partial characterization of a transformation-associated sequence from human nasopharyngeal carcinoma. Mol. Carcinog., 4: 297-307. DOI: 10.1002/mc.2940040408

Chen, Z. and J. Gu, 2007. Immunoglobulin G expression in carcinomas and cancer cell lines. FASEB J., 21: 2931-2938. DOI: 10.1096/fj.07-8073com

Chen, Z., X. Huang, J. Ye, P. Pan and Q. Cao et al., 2010. Immunoglobulin G is present in a wide variety of soft tissue tumors and correlates well with proliferation markers and tumor grades. Cancer, 116: 1953-1963. DOI: 10.1002/encr.24892

Chen, Z., X. Qiu and J. Gu, 2009. Immunoglobulin expression in non-lymphoid lineage and neoplastic cells. Am. J. Path., 174: 1139-1148. DOI: 10.2353/apjpath.2009.080879

Dudley, D.D., J. Chaudhuri, C.H. Bassing and F.W. Alt, 2005. Mechanism and control of V(D)J recombination versus class switch recombination: Linkage with somatic hypermutation. Annu. Rev. Immunol., 20: 165-196. DOI: 10.1146/annurev.immunol.20.090501.112049

Hu, D., H. Zheng, H. Liu, M. Li and W. Ren et al., 2008. Immunoglobulin expression and its biological significance in cancer cells. Cell Mol. Immunol., 5: 319-324. DOI: 10.1038/cmi.2008.39

Hu, D., Z. Duan, M. Li, Y. Jiang and H. Liu et al., 2011. Heterogeneity of aberrant immunoglobulin expression in cancer cells. Cell. Mol. Immunol., 8: 479-485. DOI: 10.1038/cmi.2011.25

Hu, J., Y. Deng and S. Zheng, 2002. Expression of a novel immunoglobulin gene SNC73 in human cancer and its significance. Zhonghua Zhong Liu Za Zhi, 24: 38-40. PMID: 11977634

Hu, J.B., S. Zheng and Y.C. Deng, 2003. Expression of a novel immunoglobulin gene SNC73 in human cancer and non-cancerous tissues. World J. Gastroenterol., 9: 1054-1057. PMID: 12717855

Huang, J., L. Zhang, T. Ma, P. Zhang and X. Qiu, 2009. Expression of immunoglobulin gene with classical V-(D)-J rearrangement in mouse testis and epididymis. J. Histochem. Cytochem., 57: 339-349. DOI: 10.1369/jhc.2008.951434

Huang, J., X. Sun, Y. Mao, X. Zhu and P. Zhang et al., 2008. Expression of immunoglobulin gene with classical V-(D)-J rearrangement in mouse brain neurons. Int. J. Biochem. Cell Biol., 40: 1604-1615. DOI: 10.1016/j.biocel.2007.12.004

Iannello, A. and A. Ahmad, 2005. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev., 24: 487-499. PMID: 16408158

Jung, D., C. Giallourakis, R. Mostoslavsky and F.W. Alt, 2006. Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu. Rev. Immunol., 24: 541-570. DOI: 10.1146/annurev.immunol.23.021704.115830

Kimoto, Y., 1998. Expression of heavy-chain constant region of immunoglobulin and T-cell receptor gene transcripts in human non-hematopoietic tumor cell lines. Genes Chromosomes Cancer, 22: 83-86. DOI: 10.1002/(sici)1098-2264(1998)22:1<83::aid-gccl2>3.0.co;2-o

Lee, C.Y., K.W. Chen, F.S. Sheu, A. Tsang and K.C. Chao et al., 1992. Studies of a tumor-associated antigen, COX-1, recognized by a monoclonal antibody. Cancer Immunol. Immunother., 35: 19-26. PMID: 1611619

Lee, G. and B. Ge, 2009. Cancer cell expressions of immunoglobulin heavy chains with unique carbohydrate-associated biomarker. Cancer Biomarkers, 5: 177-188. PMID: 19729827

Lee, G. and B. Ge, 2010. Inhibition of in vitro tumor cell growth by RP215 monoclonal antibody and antibodies raised against its anti-idiotype antibodies. Cancer Immunol. Immunother., 59: 1347-1356. PMID: 20473495
Lee, G. and P. Azadi, 2012. Peptide mapping and glycoanalysis of cancer cell-expressed glycoproteins CA215 recognized by RP215 monoclonal antibody. J. Carbohydr. Chem., 31: 10-30. DOI: 10.1080/07328303.2011.626544

Lee, G., 2009. Cancer cell-expressed immunoglobulins: CA215 as a pan cancer marker and its diagnostic applications. Cancer Biomark., 5: 137-142. PMID: 19407368

Lee, G., A.P. Cheung, B. Ge, M. Zhu and P.P. Li et al., 2010. Monoclonal anti-idiotype antibodies against carbohydrate-associated epitope for anti-cancer vaccine development. J. Vaccines. Vaccin., 1: 106-106.

Lee, G., E. Laflamme, C.H. Chien and H.H. Ting, 2008. Molecular identity of a pan cancer marker, CA215. Cancer Biol. Ther., 7: 2007-2014. PMID: 19158477

Lee, G., Q. Wu, C.H. Li, H.H. Ting and C.H. Chien, 2006. Recent studies of a new carbohydrate-associated pan cancer marker, CA215. J. Clin. Ligand Assay, 29: 47-51.

Lee, G., R.A. Chu and H.H. Ting, 2009a. Preclinical assessment of anti-cancer drugs by using RP215 monoclonal antibody. Cancer Biol. Therapy, 8: 161-166. PMID: 19029818

Lee, G., B. Ge, T.K. Huang, G. Zheng and J. Duan et al., 2009b. Positive identification of CA215 pan cancer biomarker from serum specimens of cancer patients. Cancer Biomarkers, 6: 111-117.

Lee, G., A.P. Cheung, B. Ge, M. Zhu and B. Giolma et al., 2012a. CA215 and GnRH receptor as targets for cancer therapy. Cancer Immunol. Immunother., 61: 89-99.

Li, J., C. Tan, Q. Xiang, X. Zhang and J. Ma et al., 2001. Proteomic detection of changes in protein synthesis induced by NGX6 transfected in human nasopharyngeal carcinoma cells. J. Protein Chem., 20: 265-271. PMID: 11565907

Li, M., D.Y. Feng, W. Ren, L. Zheng and H. Zheng et al., 2004. Expression of immunoglobulin kappa light chain constant region in abnormal human cervical epithelial cells. Int. J. Biochem. Cell Biol., 36: 2250-2257. DOI: 10.1016/j.biocel.2004.03.017

Li, M., H. Zheng, Z. Duan, H. Liu and D. Hu et al., 2012. Promotion of cell proliferation and inhibition of ADCC by cancerous immunoglobulin expressed in cancer cell lines. Cell. Mol. Immunol., 9: 54-61. DOI: 10.1038/cmi.2011.40

Liu, H., H. Zheng, Z. Duan, DuoSha Hu and M. Li et al., 2009. LMP1-augmented kappa intron enhancer activity contributes to upregulation expression of Ig kappa light chain via NF-kappaB and AP-1 pathways in nasopharyngeal carcinoma cells. Mol. Cancer, 8: 92-92. DOI: 10.1186/1476-4598-8-92

Liu, Y., Z. Chen, N. Niu, Q. Chang and R. Deng et al., 2012. IgG gene expression and its possible significance in prostate cancers. Prostate, 72: 690-701. DOI: 10.1002/pros.21476

Muramatsu, M., K. Kinoshita, S. Fagarasan, S. Yamada and Y. Shinkai et al., 2000. Class switch recombination and hypermutation require Activation-Induced Cytidine Deaminase (AID), a potential RNA editing enzyme. Cell, 102: 553-563. DOI: 10.1016/s0092-8674(00)00078-7

Niu, N., J. Zhang, Y. Guo, Y. Zhao and C. Korteweg et al., 2011a. Expression and distribution of immunoglobulin G and its receptors in the human nervous system. Int. J. Biochem. Cell Biol., 43: 556-563. DOI: 10.1016/j.biocel.2010.12.012

Niu, N., J. Zhang, Y. Sun, S. Wang and C. Korteweg et al., 2011b. Expression and distribution of immunoglobulin G and its receptors in an immune privileged site: The eye. Cell. Mol. Life Sci., 68: 2481-2492. PMID: 21061041

O’Neill, L. A. J., 2008. Toll-like receptors in cancer. Oncogene, 27: 158-160. DOI: 10.1038/sj.onc.1210903
Okabe, H., S. Satoh, T. Kato, O. Kitahara and R. Yanagawa et al., 2001. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: Identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res., 61: 2129-2137. PMID: 11280777

Papavasiliou, F.N. and D.G. Schatz, 2002. Somatic hypermutation of immunoglobulin genes: Merging mechanisms for genetic diversity. Cell, 109: S35-S44. PMID: 11983151

Park, Y., J.H. Lee, D.J. Hong, E.Y. Lee and H.S. Kim, 2011. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin. Biochem., 44: 884-888. DOI: 10.1016/j.clinbiochem.2011.04.011

Qiu, X., W. Liu and G. Lee, 2012a. The application of RP215 monoclonal antibody in the study of proliferation, migration, chemo-resistance of cancer cells as well as cancer stem cells. Chinese Patent.

Qiu, X., X. Zhu, L. Zhang, Y. Mao and J. Zhang et al., 2003. Human epithelial cancers secrete immunoglobulin g with unidentified specificity to promote growth and survival of tumor cells. Cancer Res., 63: 6488-6495. PMID: 14559841

Qiu, Y., C. Korteweg, Z. Chen, J. Li and J. Luo et al., 2012b. Immunoglobulin G expression and its colocalization with complement proteins in papillary thyroid cancer. Mod. Pathol., 25: 36-45. DOI: 10.1038/modpathol.2011.139

So, E.Y. and T. Ouchi, 2010. The application of Toll like receptors for cancer therapy. Int. J. Biol. Sci., 6: 675-681. DOI: 10.7150/ijbs.6.675

Weber, J., 2007. Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events. Oncologist, 12: 864-872. DOI: 10.1634/theoncologist.12-7-864

Winkel, J.G.V.D. and C.L. Anderson, 1991. Biology of human immunoglobulin G Fc receptors. J. Leukoc. Biol., 49: 511-524. PMID: 1826726

Witherden, D.A., P. Verdino, S.E. Rieder, Olivia Garjo and R.E. Mills et al., 2010. The Functional Adhesion Molecule JAML Is a Costimulatory Receptor for Epithelial γδ T Cell Activation. Sci., 329: 1205-1210. DOI: 10.1126/science.1192698

Yang, S., M. Wang and W. You, 2002. Co-expression of immunoglobulin light chain kappa and lambda in gastric carcinoma cell. Zhonghua Zhong Liu Za Zhi, 24: 465-466. PMID: 12485500

Yoshimi, K., M. Woo, Y. Son, M. Baudry and R.F. Thompson, 2002. IgG-immunostaining in the intact rabbit brain: Variable but significant staining of hippocampal and cerebellar neurons with anti-IgG. Brain Res., 956: 53-66. DOI: 10.1016/s0006-8993(02)03479-0

Zhang, S., Y. Mao, J. Huang, T. Ma and L. Zhang et al., 2010. Immunoglobulin gene locus events in epithelial cells of lactating mouse mammary glands. Cell. Mol. Life Sci., 67: 985-994. PMID: 20033753

Zhang, L., S. Hu, C. Korteweg, Z. Chen and Y. Qiu et al., 2012. Expression of immunoglobulin G in esophageal squamous cell carcinomas and its association with tumor grade and Ki67. Hum. Pathol., 43: 423-434. DOI: 10.1016/j.humpath.2011.05.020

Zhao, Y., Y. Liu, Z. Chen, C. Korteweg and J. Gu, 2011. Immunoglobulin G (IgG) expression in human umbilical cord endothelial cells. J. Histochem. Cytochem., 59: 474-488. DOI: 10.1369/0022155411400871

Zheng, H., M. Li, H. Liu, W. Ren and D.S. Hu et al., 2007a. Immunoglobulin alpha heavy chain derived from human epithelial cancer cells promotes the access of S phase and growth of cancer cells. Cell Biol. Int., 31: 82-87. DOI: 10.1016/j.cellbi.2006.09.009

Zheng, H., M. Li, W. Ren, Liang Zeng and H.D. Liu et al., 2007b. Expression and secretion of immunoglobulin alpha heavy chain with diverse VDJ recombinations by human epithelial cancer cells. Mol. Immunol., 44: 2221-2227. DOI: 10.1016/j.molimm.2006.11.010

Zheng, J., J. Huang, Y. Mao, S. Liu and X. Sun et al., 2009. Immunoglobulin gene transcripts have distinct V_{\text{H}}DJ_{\text{H}} recombination characteristics in human epithelial cancer cells. J. Biol. Chem., 284: 13610-13619. DOI: 10.1074/jbc.M809524200

Zheng, S., J. Cao and L. Geng, 2001. Structure and expression of colorectal cancer related Immunoglobulin novel gene SNC73. Zhonghua Yi Xue Za Zhi, 81: 485-488. PMID: 11798924

Zhu, X., C. Li, X. Sun, M. Yuntao and L. Guohui et al., 2008. Immunoglobulin mRNA and protein expression in human oral epithelial tumor cells. Applied Immunohistochem. Mol. Morphol., 16: 232-238. DOI: 10.1097/PAI.0b013e31814c915a

Zhu, X., L. Wu, L. Zhang, P. Hao and S. Zhang et al., 2010. Distinct regulatory mechanism of immunoglobulin gene transcription in epithelial cancer cells. Cell. Mol. Immunol., 7: 279-286. DOI: 10.1038/cmi.2010.13